The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from GlobeNewswire (a Nasdaq OMX company)

Skymark Research Initiates Independent Research Coverage on YM BioSciences, Inc.

Tuesday, April 06, 2010

Skymark Research Initiates Independent Research Coverage on YM BioSciences, Inc.09:15 EDT Tuesday, April 06, 2010 CALGARY, Alberta, April 6, 2010 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on YM BioSciences, Inc. (NYSE Amex:YMI). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com. About SMR: Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php. The Skymark Research logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6683 About YM BioSciences, Inc. (NYSE Amex:YMI): YM BioSciences, Inc. (NYSE Amex:YMI) is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. SMR Disclosure: Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures. CONTACT: Skymark Research Dylan Boyle 480-626-1911 info@skymarkresearch.com